About Us


  • James A. Bianco, M.D.

    President and Chief Executive Officer

    James A. Bianco, M.D., is the principal founder of CTI BioPharma Corp. and is the Company’s President & Chief Executive Officer, and Director. Dr. Bianco has been responsible for securing more than $1.8 billion in operating capital and is the chief architect of the company’s portfolio strategy, leading the acquisition, development, and commercialization of novel agents that improve the safety and efficacy of existing standard-of-care chemotherapies or have unique mechanisms of action.

    • Acquisition of pacritinib
    • EMA approval of pixantrone
    • In-licensing of tosedostat
    • Acquisition of Zevalin and successful submission of sBLA expanding label indication to front-line consolidation
    • Acquisition of Novuspharma (pixantrone)
    • NDA and MAA approval of Trisenox
    • Acquisition of PolarX (Trisenox)

    Prior to founding CTI BioPharma, Dr. Bianco was an Assistant Member in the clinical research division of the Fred Hutchinson Cancer Research Center (FHCRC) and an Assistant Professor of Medicine at the University of Washington. From 1990 to 1992, Dr. Bianco was the director of the Bone Marrow Transplant Program at the Veterans Administration Medical Center in Seattle. Dr. Bianco currently serves on the board of directors of the Seattle Symphony and the Seattle Symphony Foundation. He received his B.S. degree in Biology and Physics from New York University and his M.D. from Mount Sinai School of Medicine.

  • Jack W. Singer, M.D.

    EVP, Chief Scientific Officer, Interim Chief Medical Officer and Global Head of Translational Medicine


    Jack W. Singer, M.D., is a founder of CTI BioPharma and currently serves as the Company’s Executive Vice President, Chief Scientific Officer, Interim Chief Medical Officer and Global Head of Translational Medicine. Dr. Singer has been one of the Company’s directors since its inception in September 1991. From 2004 to June 2012, Dr. Singer was the Company’s Chief Medical Officer. From July 1995 to January 2004, Dr. Singer was Executive Vice President, Research Program Chairman, and from April 1992 to July 1995, he served as Executive Vice President, Research and Development. He also serves on the board of directors of DiaKine Therapeutics Inc.

    Prior to joining CTI, Dr. Singer was Professor of Medicine at the University of Washington and full Member of the Fred Hutchinson Cancer Research Center. From 1975 to 1992, he was the Chief of Medical Oncology at the Veterans Administration Medical Center in Seattle. Dr. Singer received his M.D. from State University of New York, Downstate Medical College.

  • Bruce J. Seeley

    EVP, Chief Commercial Officer

    Bruce J. Seeley joined CTI BioPharma in July 2015 as Executive Vice President, Chief Commercial Officer. Mr. Seeley leads CTI BioPharma’s commercial organization worldwide, including sales, marketing, commercial operations, medical affairs and supply chain.

    Mr. Seeley has more than 25 years of global commercial experience and a proven track record of successfully launching products in various markets and regulatory environments. Most recently, Mr. Seeley was Senior Vice President and General Manager of Diagnostics at NanoString Technologies Inc. overseeing the launch of the diagnostic product PROSIGNA® for early stage breast cancer. Previously, he was Executive Vice President of Commercial at Seattle Genetics where he built and led the commercial organization, including marketing, sales and managed markets, and successfully launched the company’s first product, ADCETRIS®, a targeted therapy for lymphoma. He also previously held key leadership positions in marketing at Genentech (now a member of the Roche Group), where he led the launch of HERCEPTIN® in adjuvant breast cancer. Earlier in his career he held various commercial roles at Aventis Pharmaceuticals Inc. (a part of Sanofi) and Bristol-Myers Squibb Co. Mr. Seeley received a B.A. In Sociology from the University of California at Los Angeles.

  • Matthew J. Plunkett, Ph.D.

    EVP, Chief Business Officer

    Matthew J. Plunkett, Ph.D., was named Executive Vice President, Chief Business Officer, in December 2015. He joined CTI BioPharma in September 2012 as Executive Vice President, Corporate Development. Dr. Plunkett leads CTI BioPharma’s partnering strategy including development collaborations, licensing agreements, and strategic alliances.

    Dr. Plunkett has more than 15 years’ experience in the biopharmaceutical industry, spanning basic research, investment banking, and executive operational roles. Most recently, Dr. Plunkett was Chief Financial Officer at the California Institute for Regenerative Medicine, a $3 billion fund for California stem cell research. Previously, he was Vice President and Chief Financial Officer at iPierian, a privately held development-stage biotechnology company. He also spent nine years at Oppenheimer & Co. and its U.S. predecessor, CIBC World Markets, most recently serving as Managing Director and head of West Coast Biotechnology. He has advised on more than 70 completed transactions for companies in the U.S., Europe and Australia, including more than $4 billion in equity and equity-linked transactions and $1 billion in merger, acquisition and other financial advisory transactions. He began his scientific career at Sunesis Pharmaceuticals and Axys Advanced Technologies.

    Dr. Plunkett received a Ph.D. in Organic Chemistry from the University of California, Berkeley, and a B.S. in Chemistry from Harvey Mudd College, Claremont, California.

  • Louis A. Bianco

    EVP, Finance and Administration

    Louis A. Bianco is a founder of CTI BioPharma and has been the Company’s Executive Vice President, Finance and Administration since February 1992. He was a Director of CTI BioPharma from the Company’s inception in September 1991 to April 1992 and from April 1993 to April 1995. From January 1989 through January 1992, Mr. Bianco was a Vice President at Deutsche Bank Capital Corporation in charge of risk management. Mr. Bianco is a Certified Public Accountant and received his M.B.A. from New York University.

  • Nancy L. Boman, M.D., Ph.D.

    SVP, Clinical Development and Regulatory Affairs

    Nancy L. Boman joined CTI BioPharma in April 2008 as Vice President, Clinical Development and Regulatory Affairs. Dr. Boman is responsible for leading Clinical Development and Regulatory Affairs departments, including clinical operations, project management and drug safety.

    Dr. Boman has more than 20 years’ experience in the biopharmaceutical industry and has successfully filed more than 15 marketing applications in the United States, Europe, Canada, Australia and Japan. Her experience spans pre-clinical through Phase 4 drug development of both small molecules and biologics for a broad range of therapeutic areas: oncology, ophthalmology, anti-viral, endocrinology, neurology and cardiology. Dr. Boman has established regulatory affairs departments for two companies and has direct experience with the U.S. Food and Drug Administration and other regulatory agencies.

    Dr. Boman previously served as Vice President, Clinical Development and Regulatory Affairs at Acucela Inc. where she hired a team of approximately 30 employees and notably led a Phase 3 program for the treatment of dry eye and development of another drug in Phase 1/2 for the treatment of dry macular degeneration. From 2005 to 2007, Dr. Boman served at Genentech as Associate Director, Clinical Regulatory Affairs lead for the Herceptin®, Rituxan®, Tarceva® franchises and 10 additional Phase 1 and 2 oncology development programs. From 2003 to 2005, Dr. Boman served at Amgen in progressively senior roles leading to Senior Manager, CMC Regulatory Affairs where she led the small molecule regulatory affairs CMC group for global regulatory activities. Prior to 2003, Dr. Boman served in a variety of positions at AnorMED Inc., QLT Inc., Inex Pharmaceuticals Corp. and Canadian Liposome Co.

    Dr. Boman earned her M.D., a Ph.D. in biochemistry and a B.S. in general science/human physiology from the University of British Columbia, Vancouver, British Columbia.

  • Monique M. Greer

    SVP, Corporate Communications and Investor Relations

    Monique M. Greer joined CTI BioPharma in November 2012 as Senior Vice President, Corporate Communications and Investor Relations. Greer leads CTI’s global communications to media, investor, patient and employee audiences. Her expertise includes corporate communications, investor and media relations, and advocacy relations in support of product development, commercialization and strategic initiatives.

    Greer has more than 17 years’ strategic communications experience in the biopharmaceutical industry. Most recently, she was Vice President of Corporate Communications and Investor Relations at Allos Therapeutics Inc., a commercial-stage hematology/oncology biopharmaceutical company acquired by Spectrum Pharmaceuticals in September 2012. Previously, she served as Senior Associate in the Corporate Communications and Investor Relations San Francisco practice for WCG, a global communications agency. Greer also has served as Senior Director, Corporate Communications and Investor Relations for Dendreon Corporation, as well as Director, Corporate Communications for Heska Corporation. Greer received a bachelor of science in Marketing and International Business from Northeastern University, Boston.

You Are Leaving CTI BioPharma

You have selected a link to a third-party website. This link is provided solely as a convenience to you and not as an endorsement by CTI BioPharma of such third-party website. CTI BioPharma is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.

Continue to the Requested Site
Return to CTI BioPharma

Hello! We are pleased to announce that Cell Therapeutics has changed its name to

Enter Site